Nebenwirkungen · Xgeva
XGEVA 120 mg solution for injection XGEVA 120 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 10
HOS-124662 · Präparat HOS-095905
In the clinical trial programme for GCTB, atypical femoral fractures have been reported commonly in patients treated with XGEVA. In study 6, incidence of confirmed AFF was 0.95% (5/526) in patients with giant cell tumour of bone. In the follow up study 7, the incidence of confirmed AFF was 3.9% (2/51) of patients exposed to denosumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T11:39:12Z · SHA-256 128fc1cc30bb902fd35b573513956c486b321d921f1c9f82cbb86938b613ea4c · Passage 4c9820c19aea14703d001ea19e9afb946076288037a9c82f368aa6542c52708d · Zeichen 11769–12105 im Abschnitt